Darolutamide(BAY1841788, Nubeqa) + Enzalutamide
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Biochemically Recurrent Prostate Cancer
Conditions
Biochemically Recurrent Prostate Cancer
Trial Timeline
Dec 19, 2022 → Dec 4, 2024
NCT ID
NCT05526248About Darolutamide(BAY1841788, Nubeqa) + Enzalutamide
Darolutamide(BAY1841788, Nubeqa) + Enzalutamide is a phase 2 stage product being developed by Bayer for Biochemically Recurrent Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT05526248. Target conditions include Biochemically Recurrent Prostate Cancer.
What happened to similar drugs?
0 of 1 similar drugs in Biochemically Recurrent Prostate Cancer were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05526248 | Phase 2 | Completed |
Competing Products
2 competing products in Biochemically Recurrent Prostate Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Durvalumab + Olaparib | AstraZeneca | Phase 2 | 27 |
| Darolutamide (BAY1841788, Nubeqa) | Bayer | Phase 3 | 41 |